Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

This network meta-analysis of fourteen randomized controlled trials places it high in the evidence hierarchy for comparing glucagon receptor agonists. Retatrutide was associated with the largest weight and HbA1c reductions but ranked lower on tolerability than mazdutide. The authors call for head-to-head trials to confirm the indirect comparisons.